Cargando…

PPARγ Agonists: Potential as Therapeutics for Neovascular Retinopathies

The angiogenic, neovascular proliferative retinopathies, proliferative diabetic retinopathy (PDR), and age-dependent macular degeneration (AMD) complicated by choroidal neovascularization (CNV), also termed exudative or “wet” AMD, are common causes of blindness. The antidiabetic thiazolidinediones (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pershadsingh, Harrihar A., Moore, David M.
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2008
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2396446/ https://www.ncbi.nlm.nih.gov/pubmed/18509499 http://dx.doi.org/10.1155/2008/164273

Ejemplares similares

Therapeutic potential of PPARγ natural agonists in liver diseases
por: Wu, Liwei, et al.
Publicado: (2020)

PPARγ Agonists: Emergent Therapy in Endometriosis
por: Vallée, Alexandre, et al.
Publicado: (2021)

PPARα Agonist Oral Therapy in Diabetic Retinopathy
por: Tomita, Yohei, et al.
Publicado: (2020)

PPARγ Agonists: Blood Pressure and Edema
por: Blazer-Yost, Bonnie L.
Publicado: (2010)

PPAR-γ: Therapeutic Potential for Multiple Sclerosis
por: Drew, Paul D., et al.
Publicado: (2008)

Therapeutic Potential of PPARγ Activation in Stroke
por: Vemuganti, Raghu
Publicado: (2008)

Therapeutic Effects of PPARα Agonist on Ocular Neovascularization in Models Recapitulating Neovascular Age-Related Macular Degeneration
por: Qiu, Fangfang, et al.
Publicado: (2017)

PPARγ Agonist Beyond Glucose Lowering Effect
por: Sugawara, Akira, et al.
Publicado: (2011)

Bronchopulmonary Dysplasia: Crosstalk Between PPARγ, WNT/β-Catenin and TGF-β Pathways; The Potential Therapeutic Role of PPARγ Agonists
por: Lecarpentier, Yves, et al.
Publicado: (2019)

The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists
por: Tsukahara, Tamotsu
Publicado: (2012)

PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia
por: Harnchoowong, Sarawin, et al.
Publicado: (2017)

PPARγ and Its Agonists in Chronic Kidney Disease
por: Ma, Yuhua, et al.
Publicado: (2020)

Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015)

Understanding PPARγ and Its Agonists on Trophoblast Differentiation and Invasion: Potential Therapeutic Targets for Gestational Diabetes Mellitus and Preeclampsia
por: Qin, Yushu, et al.
Publicado: (2023)

Obesity and the microbiome in atopic dermatitis: Therapeutic implications for PPAR-γ agonists
por: McAleer, Jeremy P.
Publicado: (2023)

Synthesis and Biological Activity of Piperine Derivatives as Potential PPARγ Agonists
por: Wang, Yanli, et al.
Publicado: (2020)

PPAR-γ Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors
por: Lichtor, Terry, et al.
Publicado: (2008)

New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy
por: Jia, Zhanjun, et al.
Publicado: (2014)

Demyelination in Multiple Sclerosis: Reprogramming Energy Metabolism and Potential PPARγ Agonist Treatment Approaches
por: Vallée, Alexandre, et al.
Publicado: (2018)

Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models
por: Chen, Ying, et al.
Publicado: (2013)

Potential Therapeutic Targets for PPARγ after Spinal Cord Injury
por: McTigue, Dana M.
Publicado: (2008)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes
por: Rogue, Alexandra, et al.
Publicado: (2011)

Screening of saponins and sapogenins from Medicago species as potential PPARγ agonists and X-ray structure of the complex PPARγ/caulophyllogenin
por: Montanari, Roberta, et al.
Publicado: (2016)

PPAR-γ Agonists and Their Effects on IGF-I Receptor Signaling: Implications for Cancer
por: Belfiore, A., et al.
Publicado: (2009)

Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists
por: Sato, H, et al.
Publicado: (2000)

Regulation of Glial Cell Functions by PPAR-γ Natural and Synthetic Agonists
por: Bernardo, Antonietta, et al.
Publicado: (2008)

PPARγ and Agonists against Cancer: Rational Design of Complementation Treatments
por: Veliceasa, Dorina, et al.
Publicado: (2008)

The Case for the Use of PPARγ Agonists as an Adjunctive Therapy for Cerebral Malaria
por: Serghides, Lena
Publicado: (2012)

Relaxation of human pulmonary arteries by PPARγ agonists
por: Kozłowska, Hanna, et al.
Publicado: (2013)

Effect of pioglitazone treatment in a patient with secondary multiple sclerosis
por: Pershadsingh, Harrihar A, et al.
Publicado: (2004)

PPAR agonists as therapeutics for CNS trauma and neurological diseases
por: Mandrekar-Colucci, Shweta, et al.
Publicado: (2013)

Synthesis, activity, and docking study of phenylthiazole acids as potential agonists of PPARγ
por: Ma, Liang, et al.
Publicado: (2016)

The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy
por: Treacy, Maxwell P, et al.
Publicado: (2012)

Biological Rationale for the Use of PPARγ Agonists in Glioblastoma
por: Ellis, Hayley Patricia, et al.
Publicado: (2014)

Therapeutic Implications of PPARγ in Human Osteosarcoma
por: Wagner, Eric R., et al.
Publicado: (2010)

Therapeutic Implications of PPARγ in Cardiovascular Diseases
por: Hasegawa, Hiroshi, et al.
Publicado: (2010)

PPAR-γ Partial Agonists in Disease-Fate Decision with Special Reference to Cancer
por: Ballav, Sangeeta, et al.
Publicado: (2022)

Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARα + γ Agonists
por: Oleksiewicz, Martin B., et al.
Publicado: (2008)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_hkpk32jmmcbfroearsj4rfhp3a